Royalty Report: Drugs, Cancer, Disease – Collection: 262605

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Biotechnology
  • Immune
  • DNA
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 262605

License Grant
The Licensor, a not-for-profit corporation formed to hold, manage, and facilitate commercialization of the university's intellectual property, grants the French Licensee a royalty-bearing exclusive license under Patent Rights to use, develop, manufacture, market, and commercialize the Licensed Subject Matter in the field of Cancer Immunotherapy, including right to use the Patent 2014/036684 – CSI-Specific chimeric Antigen Receptor Engineered Immune Cells and Chimeric Antigen Receptor (CAR) Engineered Natural Killer Cells for Cancer Immunotherapy.
License Property
Licensed Subject Matter is Cancer Immumotherapy, including US Patent United States Patent 10,227,409 granted March 12, 2019.
Field of Use
The Licensee is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.

IPSCIO Record ID: 222427

License Grant
The Licensor and the Licensee entered into a License Agreement, pursuant to which the Licensee received an exclusive, royalty-bearing license to develop and commercialize therapeutic CAR product candidates.
License Property
The Licensor develops immuno-oncology and immunology therapeutics, including, in particular, Chimeric Antigen Receptor” (CAR) T-cells  and TCR product candidates.
Field of Use
The Licensee is a  global biopharmaceutical company involved in the development and commercialization of therapies for the treatment of cancer and inflammatory diseases.

IPSCIO Record ID: 26037

License Grant
The Licensor, University, grants the Licensee and its Subsidiaries an exclusive, royalty-bearing license under the Licensor Know-How and Patent Rights to make, have made, use, and/or sell Licensed Products in the Field of human therapeutics, in the treatment of tumors. The Licensee shall have the right to grant sublicenses.
License Property
The Licensor has developed chimeric NKG2D receptor-based T cell therapies. The present inventions relate to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif.

'Patent Rights” shall mean United States Patent Application Serial No.: 11/575,878, filed April 19, 2007, United States Patent Application Serial No.: 12/407,440, filed March 19, 2009, and United States Provisional Application Serial No.: 61/255,980, filed October 29, 2009.

Field of Use
The Licensee will use its expertise and resources to practice and market the technology.

IPSCIO Record ID: 74574

License Grant
This letter of intent with a Chinese Licensor is for Super Antigen Receptor T cell (CAR-T) cocktail therapy, patents pending, manufacturing technology, and clinical data of the aforementioned therapies.
License Property
CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors.
Field of Use
The Super CAR –T Cocktail therapy has shown promise in early human clinical trials for the treatment of blood cancer, renal, cervical and hepatic cancer.

IPSCIO Record ID: 230777

License Grant
Licensor hereby grants to Licensee the exclusive license right to use the Subject Technology, including, without limitation, the right to make, have made, use, offer for sale, sell, and import any and all products, methods and services utilizing the Subject Technology and/or the Intellectual Property applicable to the Subject Technology.
License Property
Licensed Product means any product which cannot be made, used or sold without infringing on the patent rights contained in the Subject Technology.

The patents are for Chimeric antibodies comprising antigen binding sites and B and T cell epitopes, and,  Immunization of infants.

The right is for a proprietary immunotherapy platform technology.

Field of Use
The agreement is for all possible fields of use.

IPSCIO Record ID: 28923

License Grant
University hereby grants to Company and its Subsidiaries an exclusive, royalty-bearing license under Know-How and Patent Rights to make, have made, use, modify, exploit, distribute, and/or sell Licensed Products in the Field in the Territory subject to any rights which may be required to be granted to the Government of the United States of America pursuant to 35 U.S.C. §§200-211.
License Property
Technology refers to a new anti-B7-H6 Immunotherapies.

Patent Rights” shall mean Patent Cooperation Treaty Application Serial No. PCT/US2013/039812.

Field of Use
The “Field” of this Agreement shall mean Human Therapeutics.

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 256218

License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers,  under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.

Eshhar patents: US 5,906,936
US 7,741,465, Eshhar et al

Eshhar-NIH patent: US 8,211,422, Eshhar et al

Eshhar-NIH pending application: [US 13/281,560, Eshhar et al

KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.

Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.